Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center

BACKGROUND: We reported the clinical activity of gemcitabine plus capecitabine (GX) in mRCC pts previously treated with cytokines and targeted agents (Tannir et al. JU 2008). Bevacizumab (A) has activity in mRCC and has been successfully incorporated into several chemotherapy regimens in many tumor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BJU Int
Egile Nagusiak: Jonasch, Eric, Lal, Lincy S., Atkinson, Bradley J., Byfield, Stacey DaCosta, Miller, Lesley Ann, Pagliaro, Lance C., Feng, Chun, Tannir, Nizar M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648626/
https://ncbi.nlm.nih.gov/pubmed/21355978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2010.09626.x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak